HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.
Therapeutic Vaccines
Therapeutic Cancer Vaccines
- Targeted Antigens
- Therapeutic Vaccine Strategies
- Therapeutic Vaccines in the Era of Combination Strategies
Therapeutic Cancer Vaccines and Antiangiogenic Treatments Combinations
- Rationale for Vaccine Combination With AATs
- reclinical Studies Combining AATs And Vaccines
- Clinical Trials Combining AATs And Vaccines
Therapeutic Cancer Vaccines and Immune Checkpoint Blockade Combinations
- Rationale for Vaccine Combination With ICB
- Preclinical Studies Combining ICB And Vaccines
- Clinical Trials Combining ICB And Vaccines
Therapeutic vaccines are that vaccines which are directed after an infection or a disease have already occurred. The therapeutic vaccines works by activating the immunity power of a patient to fight against an infectious disease. There is difference between a therapeutic vaccine and a prophylactic vaccine as the prophylactic vaccines are administered to living organisms as a precautionary measure to prevent the infection or disease while the therapeutic vaccines are administered to individual after the individual is already affected by the disease or infection.
Committee Members
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India IVC 2025 Speakers
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United Kingdom
Elena Chiappini
University of Florence, ItalySubmit your abstract Today
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology Analysis of MPXV and VACV Peptides Underscores the Need to Consider Both MPXV Clades for Vaccine Development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Awareness and acceptability of rotavirus vaccine among mothers of under-five children in Gusau and Bungudu communities of Zamfara state, northwestern Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil